GLP-1 is used safely in non-diabetic patients to support appetite regulation and fat loss
Supports gut barrier integrity, reducing inflammation
Development of cyclic peptides with potent in vivo osteogenic activity through RaPID-based affinity maturation
Preclinical and clinical studies have uncovered several gastrointestinal effects of metformin, including stimulation of the incretin hormone glucagon-like peptide-1 (GLP-1) [8], slowing of gastric emptying [8], suppression of intestinal glucose absorption [9], inhibition of bile acid resorption [10, 11] and modulation of the gut microbiota [12]
Bnh mch vnh: truyn tnh mch 1200 mg 3000 mg hoc truyn trc tip vo ng mch vnh tri 300mg (50 mg 2 mL/pht)
The safety profile of retatrutide, even as a standalone agent, is still being characterised through ongoing trials